Golcadomide and Nivolumab in Patients with Non-Hodgkin Lymphoma with Refractory Disease After Chimeric Antigen T-cell Therapy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2025
In this combined phase I/II, open label, single arm trial to study, the safety and efficacy of combination Golcadomide and nivolumab in patients with non-Hodgkin lymphoma (NHL) who have experienced refractory/residual disease, at or after 30 days of receiving chimeric antigen T-cell (CAR-T) therapy will be studied. A dose escalation phase will be followed by a dose expansion design.
Epistemonikos ID: 5ae154dfe1914154893aad93d5dbf34814054bb2
First added on: Feb 01, 2025